Research Licence. Commencing on the Effective Date, and solely to the extent that it is agreed in any Collaboration Program or Research Pool Program that GSK should conduct work under the applicable Development Plan or Research Pool Program, Adaptimmune shall grant and hereby grants to GSK a non-exclusive licence in the Territory under the Adaptimmune Background and Adaptimmune’s interests in Collaboration Program IP, to ***Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. the extent necessary for GSK’s performance of the Collaboration Program or Research Pool Program. The licence under this Section 5.4 shall expire on the earlier of (a) the date on which Adaptimmune rejects a Nomination Notice in accordance with Section 5.3.2; or (b) an exclusive licence being granted following exercise of the relevant Option, as applicable; or (c) expiration of the applicable Option Period without exercise of the Initial Program Option or Collaboration Program Option, as applicable; or (d) Completion of the Collaboration Program or Research Pool Program. The licence under this Section 5.4 shall be sub-licenseable to GSK’s Affiliates and subcontractors to the extent such Affiliates and subcontractors are performing any obligations under any Collaboration Program or the Research Pool Program.
Research Licence. In consideration for:
Research Licence. Commencing on each Nomination Date for each Collaboration Program, and solely to the extent that it is agreed in any Collaboration Program that GSK should conduct work under the applicable Research Plan, Immunocore shall grant and hereby grants to GSK a non-exclusive licence in the Territory under the Immunocore Background, Immunocore Foreground, Joint Foreground and Platform Rights to the extent necessary for GSK’s performance of the Collaboration Program. The licence under this Section 5.4 shall expire on the earlier of (a) the date on which Immunocore rejects a Nomination Notice in accordance with Section 5.3.2; or (b) an exclusive licence being granted following exercise of the Initial Program Option or Collaboration Program Option, as applicable; or (c) expiration of the applicable Initial Program Option Period or CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Collaboration Option Period without exercise of the Initial Program Option or Collaboration Program Option, as applicable; or (d) Completion of the Collaboration Program. The licence under this Section 5.4 shall be sublicenseable to GSK’s Affiliates to the extent such Affiliates are performing any obligations under any Collaboration Program.
Research Licence. Commencing on the Amendment Effective Date and continuing until the date [***] from the Amendment Effective Date, Immunocore hereby grants to GNE a royalty-free, non-transferable, non-sublicenseable, non-exclusive research license under Immunocore’s rights in the Immunocore Background IP, the Immunocore Foreground IP, and the Joint IP solely for the purposes of completing any research related to MAGE-A4 and [***] being undertaken by GNE as at the Amendment Effective Date pursuant to the licence set out in Section 4.1.1(a) of the Existing Agreement for the purpose of jointly publishing the results. The Alliance Managers will be responsible for jointly agreeing any research and publication to be undertaken pursuant to this licence. Section 11.6 of the Agreement shall apply to any publication or disclosure of papers, presentations, abstracts or other written or oral presentation regarding results of and other information generated by GNE as a result of the exercise of its rights pursuant to this paragraph 7 except that in the event that of any disagreement by the Parties concerning such publication, the matter shall be referred for determination by the Alliance Managers.
Research Licence. Subject to You complying with the conditions in clause 4 and paying the applicable licence fees in accordance with clause 7, the University will issue You with a product serial key (Product Key) and grants to You a limited, non-exclusive, non-transferable, revocable licence (excluding any right of sub-licence) to use the Software:
Research Licence. Research license grants you a nonexclusive, non transferable limited license to use the Product only for the purpose of developing, testing, prototyping and demonstrating your application(s), and not for any other purpose. This license permits you to allow each of Your Developers to deploy the Programs on one Developer Desktop Computer. You may not use the Programs in a Shared Development Environment. For deployment and distribution of the application(s) you develop under this license for any internal data processing or for any commercial or production purposes, or if you want to use the Product for any purpose other than as permitted under this agreement, You must purchase the applicable license or You may be sued for collection and punitive damages. This license does not include support, and additional support services can be purchased.
Research Licence. (a) By this document MEPL grants to Novogen Research a non-exclusive, irrevocable, royalty-free licence under the rights granted to MEPL under the Licensed Intellectual Property to:
Research Licence. The Research Licence will come into effect on the Effective Date and unless terminated earlier in accordance with this clause or under the general law will continue in force until the earlier of:
Research Licence. XXXXXXX hereby grants to LAVA a non-exclusive, worldwide licence under the XXXXXXX Technology, solely to conduct activities allocated to LAVA under the Research Plan during the Research Term.
Research Licence
